Last Monday, the U.S. Food and Drug Administration (FDA) issued long-awaited guidance lifting a restriction on the abortion pill mifepristone for the duration of the COVID-19 public health emergency. The move permits telemedicine abortion, a combination of medication abortion—using pills to end a pregnancy—and telemedicine, which allows health providers to supervise the use of abortion pills via videoconferencing or telephone consultations.
